WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found. The ...

The study, titled “Association of IgG4-Related Disease with Human Inborn Errors of Immunity,” involved 18 patients diagnosed with IgG4-RD, all of whom underwent Whole Exome Sequencing (WES) to examine ...

Obexelimab demonstrated a statistically significant 56% reduction in the risk of IgG4-RD flare compared with placebo. Topline data were announced from a phase 3 trial evaluating obexelimab in ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

IgG4-related disease (IgG4-RD) is a chronic inflammatory condition. To treat it, doctors often prescribe corticosteroids to reduce inflammation and lower IgG4 levels. But long-term corticosteroid use ...

Adults with eosinophilic esophagitis (EoE) showed elevated levels of various food allergen–specific antibodies other than immunoglobulin G4 (IgG4), challenging the focus on IgG4 as a solitary marker ...

Please provide your email address to receive an email when new articles are posted on . B-cell depletion with inebilizumab reduced flare risk for pancreatic and/or biliary IgG4-related disease. It ...

—Investigators in Argentina recently examined a small subset of patients with immunoglobulin G4-related disease (IgG4-RD) and pulmonary findings to learn more about this immune-mediated, multiorgan ...

GlycoEra is in the sweet spot, raising $130 million to advance sugar-tagged biologics that can drive the degradation of extracellular targets. A first program targeting immunoglobulin G4 (IgG4) ...